SAB Biotherapeutics (NASDAQ:SABS) Stock Rating Reaffirmed by Oppenheimer

SAB Biotherapeutics (NASDAQ:SABS)‘s stock had its “outperform” rating reaffirmed by Oppenheimer in a report released on Thursday, Benzinga reports. They presently have a $12.00 price objective on the stock. Oppenheimer’s price objective suggests a potential upside of 341.18% from the company’s previous close.

A number of other equities research analysts also recently issued reports on the company. Brookline Capital Management began coverage on SAB Biotherapeutics in a research report on Friday, June 7th. They issued a “buy” rating and a $8.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of SAB Biotherapeutics in a research note on Monday, August 12th. Finally, Chardan Capital reiterated a “buy” rating and set a $25.00 price target on shares of SAB Biotherapeutics in a report on Monday. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, SAB Biotherapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $12.75.

SAB Biotherapeutics Stock Performance

Shares of NASDAQ SABS traded down $0.08 during mid-day trading on Thursday, reaching $2.72. 1,544 shares of the company’s stock traded hands, compared to its average volume of 14,377. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.07. The business has a 50-day simple moving average of $2.76 and a 200 day simple moving average of $3.54. SAB Biotherapeutics has a 1-year low of $2.16 and a 1-year high of $10.50.

SAB Biotherapeutics (NASDAQ:SABS) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.79) EPS for the quarter, topping the consensus estimate of ($1.13) by $0.34. The business had revenue of $0.26 million for the quarter. SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.04%. As a group, sell-side analysts anticipate that SAB Biotherapeutics will post -3.59 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of SABS. First PREMIER Bank purchased a new stake in SAB Biotherapeutics during the 2nd quarter valued at about $60,000. Commodore Capital LP purchased a new position in shares of SAB Biotherapeutics in the 4th quarter worth $1,259,000. BVF Inc. IL bought a new stake in shares of SAB Biotherapeutics during the 4th quarter valued at about $6,310,000. Finally, RTW Investments LP purchased a new stake in SAB Biotherapeutics during the fourth quarter valued at approximately $6,310,000. 7.82% of the stock is currently owned by institutional investors.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.